CytoDyn Inc. | 10-Q: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD 0.

EBIT: As of FY2026 Q1, the actual value is USD -4.363 M.

Operational Metrics

• Net Loss: The company reported a net loss of $5.54 million for the three months ended August 31, 2025, compared to a net income of $19.23 million for the same period in 2024, primarily due to a one-time return of clinical expenses in the prior year.
• Operating Expenses: Total operating expenses were $4.95 million for the three months ended August 31, 2025, compared to -$22.44 million for the same period in 2024, reflecting a significant increase due to the absence of the prior year’s clinical expense return.
• General and Administrative Expenses: Increased by 6% to $1.71 million for the three months ended August 31, 2025, from $1.61 million in the same period in 2024.
• Research and Development Expenses: Increased significantly to $3.23 million for the three months ended August 31, 2025, from -$24.05 million in the same period in 2024, due to the absence of the prior year’s clinical expense return.

Cash Flow

• Operating Cash Flow: Net cash used in operating activities was $2.45 million for the three months ended August 31, 2025, compared to net cash provided by operating activities of $5.44 million for the same period in 2024.
• Financing Cash Flow: Net cash used in financing activities was $0.12 million for the three months ended August 31, 2025, compared to net cash provided by financing activities of $9.67 million for the same period in 2024.

Unique Metrics

• Convertible Notes: As of August 31, 2025, the outstanding balance of convertible notes, including accrued interest, was approximately $43.78 million.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue the Phase II trial of leronlimab in patients with relapsed/refractory micro-satellite stable colorectal cancer and conduct additional studies exploring leronlimab’s therapeutic potential in other solid-tumor oncology indications, including metastatic Triple-Negative Breast Cancer.
• Non-Core Business: The company is researching and developing a new or modified long-acting version of leronlimab.
• Priority: The company intends to finance its future development activities and working capital needs primarily from the sale of equity and debt securities, combined with additional funding from other sources.